Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Receivables (2019 - 2025)

Bicycle Therapeutics' Receivables history spans 7 years, with the latest figure at $35.6 million for Q4 2025.

  • For Q4 2025, Receivables changed 0.15% year-over-year to $35.6 million; the TTM value through Dec 2025 reached $35.6 million, changed 0.15%, while the annual FY2025 figure was $35.6 million, 0.15% changed from the prior year.
  • Receivables reached $35.6 million in Q4 2025 per BCYC's latest filing, down from $46.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $76.5 million in Q1 2023 to a low of $1.0 million in Q4 2021.
  • Average Receivables over 5 years is $32.1 million, with a median of $26.3 million recorded in 2022.
  • Peak YoY movement for Receivables: crashed 93.17% in 2021, then soared 2020.7% in 2022.
  • A 5-year view of Receivables shows it stood at $1.0 million in 2021, then skyrocketed by 2020.7% to $21.2 million in 2022, then rose by 13.35% to $24.0 million in 2023, then skyrocketed by 48.31% to $35.7 million in 2024, then decreased by 0.15% to $35.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Receivables are $35.6 million (Q4 2025), $46.3 million (Q1 2025), and $35.7 million (Q4 2024).